350 related articles for article (PubMed ID: 18176597)
21. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer.
Murad YM; Clay TM
BioDrugs; 2009; 23(6):361-75. PubMed ID: 19894778
[TBL] [Abstract][Full Text] [Related]
22. Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion.
Ilvesaro JM; Merrell MA; Li L; Wakchoure S; Graves D; Brooks S; Rahko E; Jukkola-Vuorinen A; Vuopala KS; Harris KW; Selander KS
Mol Cancer Res; 2008 Oct; 6(10):1534-43. PubMed ID: 18922969
[TBL] [Abstract][Full Text] [Related]
23. IFN-alpha and novel strategies of combination therapy for cancer.
Bracci L; Proietti E; Belardelli F
Ann N Y Acad Sci; 2007 Sep; 1112():256-68. PubMed ID: 17567945
[TBL] [Abstract][Full Text] [Related]
24. Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications.
Guiducci C; Coffman RL; Barrat FJ
J Intern Med; 2009 Jan; 265(1):43-57. PubMed ID: 19093959
[TBL] [Abstract][Full Text] [Related]
25. TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients.
Wu P; Wu J; Liu S; Han X; Lu J; Shi Y; Wang J; Lu L; Cao X
Clin Immunol; 2008 Oct; 129(1):40-8. PubMed ID: 18684674
[TBL] [Abstract][Full Text] [Related]
26. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.
Toschi L; Jänne PA
Clin Cancer Res; 2008 Oct; 14(19):5941-6. PubMed ID: 18829470
[TBL] [Abstract][Full Text] [Related]
27. [Immunological aspects of anticancer chemotherapy].
Zitvogel L; Tesniere A; Apetoh L; Ghiringhelli F; Kroemer G
Bull Acad Natl Med; 2008 Oct; 192(7):1469-87; discussion 1487-9. PubMed ID: 19445369
[TBL] [Abstract][Full Text] [Related]
28. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia.
Spaner DE; Masellis A
Leukemia; 2007 Jan; 21(1):53-60. PubMed ID: 17066089
[TBL] [Abstract][Full Text] [Related]
29. Potential of Toll-like receptor 9 agonists in combined anticancer immunotherapy strategies: synergy of PAMPs and DAMPs?
Holtick U; Klein-Gonzalez N; von Bergwelt-Baildon MS
Immunotherapy; 2011 Mar; 3(3):301-4. PubMed ID: 21395370
[No Abstract] [Full Text] [Related]
30. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis.
Chiron D; Pellat-Deceunynck C; Maillasson M; Bataille R; Jego G
J Immunol; 2009 Oct; 183(7):4371-7. PubMed ID: 19734228
[TBL] [Abstract][Full Text] [Related]
31. Enzastaurin.
Ma S; Rosen ST
Curr Opin Oncol; 2007 Nov; 19(6):590-5. PubMed ID: 17906457
[TBL] [Abstract][Full Text] [Related]
32. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).
Ashkenazi A; Holland P; Eckhardt SG
J Clin Oncol; 2008 Jul; 26(21):3621-30. PubMed ID: 18640940
[TBL] [Abstract][Full Text] [Related]
33. Toll-like receptor 9 agonists promote IL-8 and TGF-beta1 production via activation of nuclear factor kappaB in PC-3 cells.
Di JM; Pang J; Pu XY; Zhang Y; Liu XP; Fang YQ; Ruan XX; Gao X
Cancer Genet Cytogenet; 2009 Jul; 192(2):60-7. PubMed ID: 19596255
[TBL] [Abstract][Full Text] [Related]
34. Expression of toll-like receptor 9 in horse lungs.
Schneberger D; Caldwell S; Suri SS; Singh B
Anat Rec (Hoboken); 2009 Jul; 292(7):1068-77. PubMed ID: 19548205
[TBL] [Abstract][Full Text] [Related]
35. Regulatory molecules required for nucleotide-sensing Toll-like receptors.
Saitoh S; Miyake K
Immunol Rev; 2009 Jan; 227(1):32-43. PubMed ID: 19120473
[TBL] [Abstract][Full Text] [Related]
36. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides.
Mutwiri G; van Drunen Littel-van den Hurk S; Babiuk LA
Adv Drug Deliv Rev; 2009 Mar; 61(3):226-32. PubMed ID: 19162103
[TBL] [Abstract][Full Text] [Related]
37. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
Halterman PA
Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
[TBL] [Abstract][Full Text] [Related]
38. Development of vorinostat: current applications and future perspectives for cancer therapy.
Richon VM; Garcia-Vargas J; Hardwick JS
Cancer Lett; 2009 Aug; 280(2):201-10. PubMed ID: 19181442
[TBL] [Abstract][Full Text] [Related]
39. Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application.
Bai L; Chen W; Chen J; Li W; Zhou L; Niu C; Han W; Cui J
J Transl Med; 2017 Feb; 15(1):51. PubMed ID: 28241765
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological inhibition of TGFβ as a strategy to augment the antitumor immune response.
Hanks BA; Morse MA
Curr Opin Investig Drugs; 2010 Dec; 11(12):1342-53. PubMed ID: 21154116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
